» Articles » PMID: 31862541

Loss of Presenilin 2 Age-dependently Alters Susceptibility to Acute Seizures and Kindling Acquisition

Overview
Journal Neurobiol Dis
Specialty Neurology
Date 2019 Dec 22
PMID 31862541
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Patients with Alzheimer's disease (AD) experience seizures at higher rates than the general population of that age, suggesting an underexplored role of hyperexcitability in AD. Genetic variants in presenilin (PSEN) 1 and 2 genes lead to autosomal dominant early-onset AD (ADAD); patients with PSEN gene variants also report seizures. Pharmacological control of seizures in AD may be disease-modifying. Preclinical efficacy of FDA-approved antiseizure drugs (ASDs) is well defined in young adult rodents; however, the efficacy of ASDs in aged rodents with chronic seizures is less clear. The mechanism by which ADAD genes lead to AD remains unclear, and even less studied is the pathogenesis of epilepsy in AD. PSEN variants generally all result in a biochemical loss of function (De Strooper, 2007). We herein determined whether well-established models of acute and chronic seizure could be used to explore the relationship between AD genes and seizures through investigating whether loss of normal PSEN2 function age-dependently influenced susceptibility to seizures and/or corneal kindling acquisition. PSEN2 knockout (KO) and age-matched wild-type (WT) mice were screened from 2- to 10-months-old to establish age-dependent focal seizure threshold. Additionally, PSEN2 KO and WT mice aged 2- and 8-months-old underwent corneal kindling such that mice were aged 3- and 9-months old at the beginning of ASD efficacy testing. We then defined the dose-dependent efficacy of mechanistically distinct ASDs on kindled seizures of young versus aged mice to better understand the applicability of corneal kindling to real-world use for geriatric patients. PSEN2 KO mice demonstrated early-life reductions in seizure threshold. However, kindling acquisition was delayed in 2-month-old PSEN2 KO versus WT mice. Young male WT mice took 24.3 ± 1.3 (S.E.M.) stimulations to achieve kindling criterion, whereas age-matched PSEN2 KO male mice took 41.2 ± 1.1 stimulations (p < .0001). The rate of kindling acquisition of 8-month-old mice was no longer different from WT. This study demonstrates that loss of normal PSEN2 function is associated with age-dependent changes in the in vivo susceptibility to acute seizures and kindling. Loss of normal PSEN2 function may be an underexplored molecular contributor to seizures. The use of validated models of chronic seizures in aged rodents may uncover age-related changes in susceptibility to epileptogenesis and/or ASD efficacy in mice with AD-associated genotypes, which may benefit the management of seizures in AD.

Citing Articles

The Bidirectional Relationship Between Epilepsy and Alzheimer's Disease.

Stewart D, Johnson E Curr Neurol Neurosci Rep. 2025; 25(1):18.

PMID: 39921833 DOI: 10.1007/s11910-025-01404-y.


Sex influences on hippocampal kindling-induced seizures in middle-aged mice.

Song H, Liu Y, Sun Y, Mah B, Bai Y, Zhang L Heliyon. 2024; 10(22):e40294.

PMID: 39634411 PMC: 11616523. DOI: 10.1016/j.heliyon.2024.e40294.


Altered expression of Presenilin2 impacts endolysosomal homeostasis and synapse function in Alzheimer's disease-relevant brain circuits.

Perdok A, Van Acker Z, Vrancx C, Sannerud R, Vorsters I, Verrengia A Nat Commun. 2024; 15(1):10412.

PMID: 39613768 PMC: 11607342. DOI: 10.1038/s41467-024-54777-y.


Alzheimer's disease-associated genotypes differentially influence chronic evoked seizure outcomes and antiseizure medicine activity in aged mice.

Knox K, Davidson S, Lehmann L, Skinner E, Lo A, Jayadev S bioRxiv. 2024; .

PMID: 39416203 PMC: 11482912. DOI: 10.1101/2024.10.06.616921.


Innovative drug discovery strategies in epilepsy: integrating next-generation syndrome-specific mouse models to address pharmacoresistance and epileptogenesis.

Barker-Haliski M, Hawkins N Expert Opin Drug Discov. 2024; 19(9):1099-1113.

PMID: 39075876 PMC: 11390315. DOI: 10.1080/17460441.2024.2384455.


References
1.
Palop J, Mucke L . Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol. 2009; 66(4):435-40. PMC: 2812914. DOI: 10.1001/archneurol.2009.15. View

2.
Barker-Haliski M, Harte-Hargrove L, Ravizza T, Smolders I, Xiao B, Brandt C . A companion to the preclinical common data elements for pharmacologic studies in animal models of seizures and epilepsy. A Report of the TASK3 Pharmacology Working Group of the ILAE/AES Joint Translational Task Force. Epilepsia Open. 2018; 3(Suppl Suppl 1):53-68. PMC: 6210039. DOI: 10.1002/epi4.12254. View

3.
Payne A, Gerdes B, Naumchuk Y, McCalley A, Kaja S, Koulen P . Presenilins regulate the cellular activity of ryanodine receptors differentially through isotype-specific N-terminal cysteines. Exp Neurol. 2013; 250:143-50. PMC: 3843983. DOI: 10.1016/j.expneurol.2013.09.001. View

4.
Broekaart D, Anink J, Baayen J, Idema S, de Vries H, Aronica E . Activation of the innate immune system is evident throughout epileptogenesis and is associated with blood-brain barrier dysfunction and seizure progression. Epilepsia. 2018; 59(10):1931-1944. DOI: 10.1111/epi.14550. View

5.
Lam A, Deck G, Goldman A, Eskandar E, Noebels J, Cole A . Silent hippocampal seizures and spikes identified by foramen ovale electrodes in Alzheimer's disease. Nat Med. 2017; 23(6):678-680. PMC: 5461182. DOI: 10.1038/nm.4330. View